Correction to “Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients”

IF 14.6 2区医学 Q1 HEMATOLOGY

HemaSphere Pub Date : 2025-09-18 DOI:10.1002/hem3.70221

引用次数: 0

Abstract

Enblad AP, Krali O, Gezelius H, et al. Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients. HemaSphere. 2025;9(7):e70176. doi:10.1002/hem3.70176

The supplemental methods mentioned in the subsection titled “DNA methylation and RNA-sequencing data” was not included in the Supporting Information. This file has been added and cited at the applicable instance in the article.

We apologize for this error.

查看原文本刊更多论文

对“597例小儿急性淋巴细胞白血病患者体外药物反应及分子谱”的修正

Enblad AP, Krali O, Gezelius H，等。597例小儿急性淋巴细胞白血病患者的体外药物反应和分子谱HemaSphere。2025; 9 (7): e70176。标题为“DNA甲基化和rna测序数据”小节中提到的补充方法未包含在支持信息中。该文件已在本文的适用实例中添加并引用。我们为这个错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

HemaSphere Medicine-Hematology

CiteScore

6.10

自引率

4.50%

发文量

2776

审稿时长

7 weeks

期刊介绍： HemaSphere, as a publication, is dedicated to disseminating the outcomes of profoundly pertinent basic, translational, and clinical research endeavors within the field of hematology. The journal actively seeks robust studies that unveil novel discoveries with significant ramifications for hematology. In addition to original research, HemaSphere features review articles and guideline articles that furnish lucid synopses and discussions of emerging developments, along with recommendations for patient care. Positioned as the foremost resource in hematology, HemaSphere augments its offerings with specialized sections like HemaTopics and HemaPolicy. These segments engender insightful dialogues covering a spectrum of hematology-related topics, including digestible summaries of pivotal articles, updates on new therapies, deliberations on European policy matters, and other noteworthy news items within the field. Steering the course of HemaSphere are Editor in Chief Jan Cools and Deputy Editor in Chief Claire Harrison, alongside the guidance of an esteemed Editorial Board comprising international luminaries in both research and clinical realms, each representing diverse areas of hematologic expertise.